Endoscopist specialty is associated with colonoscopy quality
Crohn’s disease, which affects the large and small intestines, is even more common in Canada and affects about 234 per 100,000 people, with an incidence of 13.4 per 100,000 each year. By comparison, ulcerative colitis prevalence is 58 to 157 per 100,000 in Northern Europe and about 167 per 100,000 for an area of Minnesota. Crohn’s disease prevalence ranges from 27 to 48 per 100,000 in Northern Europe to 144 per 100,000 in an area of Minnesota. Some Third World nations and areas in tropical latitudes have still lower rates. Although the reasons for these differences remain unclear, the hygiene hypothesis may help explain the distribution in Canada, said Richard Fedorak, M.D., of the University of Alberta in Edmonton, a co-author. “If you live in an environment that’s too clean or too sterile as a child your intestines are not exposed to bacteria of the same types and numbers you would be exposed to in a tropical area,” he said. which is especially true for Canada because much of the country has cold winters with little bacterial activity in the soil. Then if the genetic triggers are present, “your intestine is not able to tolerate bacteria as you get older and starts to destroy itself,” he added. Supporting this speculation, the researchers discovered differences among provinces: Nova Scotia in the Maritimes consistently had the highest rates of ulcerative colitis (19.2 incidence and 247.9 prevalence per 100,000) and Crohn’s disease (20.2 incidence and 318.5 per 100,000), Following closely is Alberta, with ulcerative colitis incidence of 11.0 and prevalence of 185.0 per 100,000 and Crohn’s disease incidence of 16.5 and prevalence of 283.0 per 100,000, and Manitoba had likewise high rates of ulcerative colitis (15.4 incidence and 248.6 prevalence per 100,000) and Crohn’s disease (15.4 incidence and 271.4 prevalence per 100,000); Whereas British Columbia, on the west coast, consistently had much lower rates of both ulcerative colitis (9.9 incidence and 162.1 prevalence per 100,000) and Crohn’s disease (8.8 incidence and 160.7 prevalence per 100,000). British Columbia proved to be an outlier, particularly for Crohn’s disease perhaps because of its milder winters, more precipitation, and “because its population ethnic make-up is somewhat different from the rest of Canada,” the researchers wrote. Much of British Columbia’s immigration in the past 20 years has been from Asia, they said.
Canadian independent medical study shows Bio-K+CL1285(R) can prevent antibiotic-associated diarrhea
Most often, antibiotic-associated diarrhea is fairly mild and clears up shortly after the patient stops taking the antibiotic. But sometimes the patient may develop colitis, an inflammation of the large intestine, often in a particularly serious form called “pseudomembranous colitis”. Any form of colitis can cause abdominal pain, fever and bloody diarrhea. Pseudomembranous colitis can be life-threatening. There is increasing awareness that good bacteria must be present in high numbers in the intestine to ensure proper function of the digestive system and maintain the delicate balance of good digestive health. About Bio-K+CL1285(R) Bio-K+CL1285(R) contains a unique, powerful, and effective patented formula of bacterial strains (Lb. Acidophilus, and Lb. Casei). It is available in the form of 98g bottles of either fresh fermented milk or soy, containing a minimum of 50 billion fresh, live and active bacteria at consumption, and as enteric-coated capsules. Bio-K+CL1285(R) is currently used in 36 Canadian hospitals and health centres, and is sold in the health specialized sections of grocery stores, pharmacies and health stores across Canada and US. About Bio-K+ International Inc. Founded in 1994, Bio-K+ International Inc. is a family-owned Canadian biotech company with its head offices located in Laval’s scientific and high-tech park. With more than 65 employees, Bio-K+ International Inc. is dedicated to the manufacture, distribution and sale of Bio-K+CL1285(R) products.
In contrast to province-wide studies from Ontario and Manitoba on endoscopy specialty and quality, our study was restricted to urban hospitals and to ambulatory care patients; thus, our findings are less generalizable. Nevertheless, in province-wide studies, the power to detect an interaction between location and specialty may be of concern, since the majority of colonoscopies are performed by gastroenterologists in urban areas and by surgeons in rural areas [ 22 ]. We determined the variability in polypectomy rates within each specialty, and found considerable variation in both specialties. Several studies have reported important variation in ADRs by specialty. Barclay et al. examined 2,053 screening colonoscopies by 12 endoscopists and found that ADRs varied from 9.4 to 32.7% [ 23 ]. Chen et al. studied the variation among 9 endoscopists who performed 10,034 colonoscopies. After adjusting for patient age and sex, detection rates for at least one adenoma ranged between 15.5 and 41.1% [ 24 ]. Imperiale et al. found that ADRs ranged from 7% to 44% among 46 endoscopists who performed 2,664 screening colonoscopies [ 7 ]. Our results mirror those of others showing variation in endoscopist performance, and further current knowledge in that considerable variation exists between as well as within specialties. Our results suggest a clinically important difference in polypectomy rates between surgeons and gastroenterologists after adjusting for patient-level factors, as well as substantial variation among all endoscopists.
visit here http://www.biomedcentral.com/1471-230X/13/78
Atlanta-Based EndoChoice Approved To Market Full-Spectrum Endoscopy System In Canada
The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers enabling doctors to see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have a single imager so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures. The Health Canada license means its Fuse system will be the first endoscopy equipment available with expanded viewing capabilities to reach Canadian patients, the company said. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The news from Health Canada enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialist customers throughout Canada . “We intend to gain market clearance in several more countries in the near future,” said Mark Gilreath, Founder and CEO at EndoChoice. “While 2013 has been an exciting year for our company, the introduction of Fuse into Canada and other markets will enable us to make 2014 even more dynamic as we bring this game-changing technology to more clinicians.” EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio.